BIOMAT Database Logo BIOMAT Database Logo

Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients. 1995

E Oravcová, and M Mistrík, and A Sakalová, and L Drgona, and T Kollár, and L Helpianska, and I Ilavská, and D Sorkovská, and S Spánik, and E Kukucková
Department of Clinical Medicine, University of Trnava, Bratislava, Slovak Republic.

20 patients with proven or suspected fungal infections were treated with the amphotericin B lipid complex (ABLC) with a daily dose of 5 mg/kg for 1-25 days. 6 patients died during the therapy due to fungal infection (3) or underlying disease (3). One patient was not evaluable. 13 patients were cured and improved. ABLC was administered in patients with renal disease avoiding the use of conventional amphotericin B (AmB) because of nephrotoxicity or after failure with AmB. Except for hypokalemia persisting after AmB in 5 patients, no systemic adverse reaction appeared. ABLC is a promising, well-tolerated and effective drug for the therapy of fungal infections after the failure of a previous antifungal therapy or after toxic reactions due to AmB.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009181 Mycoses Diseases caused by FUNGI. Fungus Diseases,Fungal Diseases,Fungal Infections,Fungus Infections,Disease, Fungal,Disease, Fungus,Diseases, Fungal,Diseases, Fungus,Fungal Disease,Fungal Infection,Fungus Disease,Fungus Infection,Infection, Fungal,Infection, Fungus,Infections, Fungal,Infections, Fungus
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000666 Amphotericin B Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela. Amphocil,Amphotericin,Amphotericin B Cholesterol Dispersion,Amphotericin B Colloidal Dispersion,Fungizone

Related Publications

E Oravcová, and M Mistrík, and A Sakalová, and L Drgona, and T Kollár, and L Helpianska, and I Ilavská, and D Sorkovská, and S Spánik, and E Kukucková
Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.
June 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
E Oravcová, and M Mistrík, and A Sakalová, and L Drgona, and T Kollár, and L Helpianska, and I Ilavská, and D Sorkovská, and S Spánik, and E Kukucková
Amphotericin B lipid complex in pediatric patients with invasive fungal infections.
August 1999, The Pediatric infectious disease journal,
E Oravcová, and M Mistrík, and A Sakalová, and L Drgona, and T Kollár, and L Helpianska, and I Ilavská, and D Sorkovská, and S Spánik, and E Kukucková
Efficacy and safety of amphotericin B lipid complex in 548 children and adolescents with invasive fungal infections.
February 2005, The Pediatric infectious disease journal,
E Oravcová, and M Mistrík, and A Sakalová, and L Drgona, and T Kollár, and L Helpianska, and I Ilavská, and D Sorkovská, and S Spánik, and E Kukucková
Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients.
February 2001, European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology,
E Oravcová, and M Mistrík, and A Sakalová, and L Drgona, and T Kollár, and L Helpianska, and I Ilavská, and D Sorkovská, and S Spánik, and E Kukucková
Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate.
December 2008, Therapeutics and clinical risk management,
E Oravcová, and M Mistrík, and A Sakalová, and L Drgona, and T Kollár, and L Helpianska, and I Ilavská, and D Sorkovská, and S Spánik, and E Kukucková
Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections.
August 2000, Clinical transplantation,
E Oravcová, and M Mistrík, and A Sakalová, and L Drgona, and T Kollár, and L Helpianska, and I Ilavská, and D Sorkovská, and S Spánik, and E Kukucková
Amphotericin B lipid complex for the treatment of invasive fungal infections.
November 2003, Expert opinion on pharmacotherapy,
E Oravcová, and M Mistrík, and A Sakalová, and L Drgona, and T Kollár, and L Helpianska, and I Ilavská, and D Sorkovská, and S Spánik, and E Kukucková
Amphotericin B lipid complex in the management of invasive fungal infections in immunocompromised patients.
November 2011, Clinical drug investigation,
E Oravcová, and M Mistrík, and A Sakalová, and L Drgona, and T Kollár, and L Helpianska, and I Ilavská, and D Sorkovská, and S Spánik, and E Kukucková
Amphotericin B lipid complex in the treatment of invasive fungal infections in liver transplant patients.
September 1997, Transplantation proceedings,
E Oravcová, and M Mistrík, and A Sakalová, and L Drgona, and T Kollár, and L Helpianska, and I Ilavská, and D Sorkovská, and S Spánik, and E Kukucková
Efficiency and safety of inhaled amphotericin B lipid complex (Abelcet) in the prophylaxis of invasive fungal infections following lung transplantation.
November 2008, Transplantation proceedings,
Copied contents to your clipboard!